Evidence map›Paper›PMID 31341417›Full record

ArticleInternational journal of medical sciences2019

Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein.

Dening Pei, Jialiang Hu, Chunming Rao, Pengcheng Yu, Hanmei Xu, Junzhi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Targeting tumor vascularization: promising strategies for vascular normalization.Journal of cancer research and clinical oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dening PeiDepartment of Biochemistry and Molecular Biology, The State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, China.
Jialiang HuThe Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
Chunming RaoKey Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 100050, China.
Pengcheng YuThe Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
Hanmei XuThe Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
Junzhi WangDepartment of Biochemistry and Molecular Biology, The State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an 710032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AP25 is an anti-tumor peptide with a high affinity for integrins. It exerts its anti-tumor activity by inhibiting angiogenesis and by directly inhibiting the growth of tumor cells. Its half-life time

Indexed as

Administration, IntravenousAnimalsCell MovementCell ProliferationDrug Screening Assays, AntitumorEndostatinsFemaleHalf-LifeHCT116 CellsHEK293 CellsHumansHuman Umbilical Vein Endothelial CellsImmunoconjugatesImmunoglobulin GMaleMiceAP25 peptideEndostatinsImmunoconjugatesImmunoglobulin GPeptide FragmentsRecombinant Fusion Proteinsanti-angiogenesisanti-tumorAP25-Fcfusion proteinhalf-life

Identifiers

PMID31341417
PMCPMC6643120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.